Since 1956, the pMDI has become the most commonly prescribed and used aerosol device in the world. While concerns about global warming have led to a worldwide ban of CFCs, new HFA-propelled pMDIs are in development, requiring an evolutionary transition in the technology. The phase-out of CFC-propelled pMDIs has stimulated the development of more efficient DPIs, but issues such as cost of device production, inspiratory flow requirement, and the effects of ambient humidity on drug delivery may limit DPI acceptance, and industry projections suggest that the DPI will not completely replace the pMDI. Holding chambers may perform differently with HFA-propelled pMDIs, but HFA-propelled pMDIs generally appear to cause less oropharyngeal deposition and to improve lung delivery while continuing to provide protection from poor hand-breath coordination. The initial offerings of the emerging HFA-propelled pMDI technology appear to be resulting in an improved pMDI.
RossDL, GabrioBJ. Advances in metered-dose inhaler technology with the development of chlorofluorocarbon-free drug delivery system. J Aerosol Med. 1999;12:151–160.
2.
ThielCG. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: DalbyRN, ByronP, FarrSY, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press; 1996: 115–123.
3.
MolinaMJ, RowlandFS. Stratospheric sink for chlorofluoromethanes: chlorine atom catalysed destruction of ozone. Nature. 1974;249:810–812.
4.
DolovichM.New delivery systems and propellants (review). Can Respir J. 1999;6(3):290–295.
5.
FinkJB, DhandR.Aerosol therapy. In: FinkJB, HuntG, editors. Clinical practice in respiratory care. Philadelphia: Lippincott Raven; 1998.
6.
AARC Clinical Practice Guideline. Selection of an aerosol delivery device. Respir Care. 1992;37(8):891–897.
DunbarCA, WatkinsAP, MilerJF. An experimental investigation of the spray issued from a pMDI using laser diagnostic techniques. J Aerosol Med. 1997;10(4):351–368.
9.
Des JardinsT.Freon-propelled bronchodilator use as a potential hazard to asthmatic patients. Respir Care. 1980;21(1):50–58.
NewhouseMT, DolovichM.Aerosol therapy in children: basic mechanisms of pediatric respiratory disease: cellular and integrative. New York: BC Decker; 1991.
12.
BreedenCC, SafirsteinBH. Albuterol and spacer-induced atrial fibrillation. Chest. 1990;98(3):762–763.
13.
SilvergladeA.Cardiac toxicity of aerosol propellants. JAMA. 1972;222(7):827–828.
14.
MorenF.Aerosol dosage forms and formulations. In: MorenF, NewhouseMT, DolovichMB, editors. Aerosols in medicine: principles, diagnosis and therapy. Amsterdam: Elsevier; 1985: 261–287.
15.
HallworthGW. The formulation and evaluation of pressurized metered-dose inhalers. In: GandertonD, JonesT, editors. Drug delivery to the respiratory tract. Chichester, England: Ellis Horwood; 1987: 87–118.
16.
DhandR, MalikSK, BalakrishnanM, VermaSR. High speed photographic analysis of aerosols produced by metered-dose inhalers. J Pharm Pharmacol. 1988;40(6):429–430.
17.
WienerMV. How to formulate aerosols to obtain the desired spray pattern. Soc Cos Chem. 1958;9:289–297.
18.
NewmanSP. Aerosol generators and delivery systems. Respir Care. 1991;36(9):939–951.
19.
LarsenJS, HahnM, EkholmB, WickKA. Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. J Asthma. 1994;31(3):193–199.
20.
GuidryGG, BrownWD, StognerSW, GeorgeRB. Incorrect use of metered-dose inhalers by medical personnel. Chest. 1992;101(1):31–33.
21.
NewmanSP, PaviaD, ClarkeSW. Simple instructions for using pressurized aerosol bronchodilators. JR Soc Med. 1980;73(11):776–779.
22.
De BlaquiereP, ChristensenDB, CarterWB, MartinTR. Use and misuse of metered-dose inhalers by patients with chronic lung disease: a controlled randomized trial of two instruction methods. Am Rev Respir Dis. 1989;140(4):910–916.
23.
HampsonNB, MuellerMP. Reduction in patient timing errors using a breath-activated metered-dose inhaler. Chest. 1994;106(2):462–465.
24.
FinkJB, WilkesW, DhandR, FaheyPJ, TobinMJ. A new method to characterize the effects of spacers and holding chambers on poor hand-breath coordination during MDI use? (abstract). Respir Care. 1998;43(10):873.
25.
SalzmanGA, PyszczynskiDR. Oropharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with Aerochamber. J Allergy Clin Immunol. 1988;81(2):424–428.
26.
ToogoodJH, BaskervilleJ, JenningsB, LefcoeNM, JohanssonSA. Use of spacer to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis. 1984;129(5):723–729.
27.
RubinBK. Pressurized metered-dose inhalers and holding chambers for inhaled glucocorticoid therapy in childhood asthma (letter). J Allergy Clin Immunol. 1999;103(6):1224–1225.
28.
ClosaRM, CeballosJM, Gomez-PapiA, GalianaAS, GutierrezC, Marti-HenneberC.Efficacy of bronchodilators administered by nebulizers versus spacer devices in infants with acute wheezing. Pediatr Pulmonol. 1998;26(5):344–348.
29.
WilliamsJR, BothnerJP, SwantonRD. Delivery of albuterol in a pediatric emergency department. Pediatr Emerg Care. 1996;12(4):263–267.
30.
CunninghamSJ, CrainEF. Reduction of morbidity in asthmatic children given a spacer device. Chest. 1994;106(3):753–757.
31.
RauJ, ZhuY.Reservoir design and dose availability with long-term metered-dose inhaler corticosteroid use. J Aerosol Med. 1998;11(1):15–26.
32.
BergE.In vitro properties of pressurized metered-dose inhalers with and without spacer devices (review). J Aerosol Med. 1995;8 Suppl 3:S3–S10; discussion S11.
33.
BarryPW, O'CallaghanC.The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br J Clin Pharmacol. 1995;40(1):76–78.
34.
O'CallaghanC, LynchJ, CantM, RobertsonC.Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug. Thorax. 1993;48(6):603–606.
GandertonD.The generation of respirable clouds from coarse powder aggregates. J Biopharm Sci. 1992;3:101–105.
39.
DolovichM, RheimR, RashidF, CoatesG, HillM, BowenB.Measurement of the particle size and dosing characteristics of a radiolabelled albuterol-sulphate lactose blend used in the SPIROS dry powder inhaler. In: DalbyRN, ByronP, FarrSY, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press; 1996: 332–335.
40.
EngelT, HeinigJH, MadsenF, NikanderK.Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler). Eur Respir J. 1990;3(9):1037–1041.
41.
PedersenS, HansenOR, FuglsangG.Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child. 1990;65(3):308–310.
42.
ThorssonL, EdsbackeS, ConradsonTB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler (P-MDI). Eur Respir J. 1994;7(10):1839–1844.
43.
SvartengrenK, LindestadPA, SvartengrenM, PhilipsonK, BylinG, CamnerP.Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med. 1995;152(1):32–37.
44.
HillLS, SlaterAL. A comparison of the performance of two modern multidose dry powder asthma inhalers. Respir Med. 1998;92(1):105–110.
45.
RajkumariNJ, ByronPR, DalbyRN. Testing of dry powder aerosol formulations in different environmental conditions. Int J Pharmacol. 1995;113:123–130.
46.
TimsinaMP, MartinGP, Van der KolkH, TushulzenE, EnthobenR.The effect of inhalation flow on the performance of a dry powder inhalation system. Int J Pharmacol. 1992;81:199–203.
47.
HindleM, ByronPR. Dose emissions from marketed dry powder inhalers. Int J Pharmacol. 1995;116:169–177.
48.
KimCS, GarciaL.Delivery characteristics of albuterol powder aerosol by rotahaler. J Aerosol Med. 1993;6:199–211.
49.
BisgaardH, IfversenM, KlugB, StamstrupK, SumbyB.Inspiratory flow rate through the Diskus/Accuhaler inhaler and Turbuhaler inhaler in children with asthma. J Aerosol Med. 1995;8:100.
50.
SmithKJ, ChangH-K, BrownKF. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. J Aerosol Med. 1998;11(4):231–245.
51.
PrimeD, GrantAC, SlaterAL, WoodhouseRN. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered-dose inhaler. Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. J Aerosol Med. 1999;12(2):75–84.
52.
PedersenS.Delivery options for inhaled therapy in children over the age of 6 years. J Aerosol Med. 1997;10 Suppl 1:S41–S44.
53.
BisgaardH.Delivery options for inhaled therapy in children under the age of 6 years. J Aerosol Med. 1997;10 Suppl 1:S37–S40.
54.
KestenS, EliasM, CartierA, ChapmanKR. Patient handling of a multidose dry powder inhalation device for albuterol. Chest. 1994;105(4):1077–1081.
55.
LeachC.Enhanced drug delivery through reformulating MDIs with HFA propellants—drug deposition and its effect on preclinical and clinical programs. In: DalbyRN, ByronP, FarrSY, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press; 1996.
56.
WoodcockA.Continuing patient care with metered-dose inhalers. J Aerosol Med. 1995;8 Suppl 2:S5–S10.
57.
JunD, CarlsonS, RossD.The effect of temperature on drug delivery characteristics of chlorofluorocarbon (CFC) and hydrofluoroalkane (HFA) metered-dose inhalers (MDIS). In: DalbyRN, ByronPR, FarrSJ, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press; 1996: 354–356.
58.
DolovichM, LeachCL. Drug delivery devices and propellants. In: BusseW, HolgateS, editors. Asthma and rhinitis. Oxford: Blackwell Science; 1999.
59.
DubusJC, RhemR, DolovichM.In vitro characterization of salbutamol generic MDIs: delviery via small spacers (abstract). Eur Respir J. 1998;12:65S.
60.
DonnellD, HarrisonLI, WardS, KlingerNM, EkholmBP, CooperKM, et al. Acute safety of the CFC-free propellant HFA-134a from a pressurized metered-dose inhaler. Eur J Clin Pharmacol. 1995;48(6):473–477.
